Compare EXG & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXG | NAMS |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2006 | 2022 |
| Metric | EXG | NAMS |
|---|---|---|
| Price | $8.67 | $18.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $50.86 |
| AVG Volume (30 Days) | 538.1K | ★ 1.8M |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,503,000.00 |
| Revenue This Year | N/A | $83.53 |
| Revenue Next Year | N/A | $23.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.25 | $17.90 |
| 52 Week High | $10.16 | $42.21 |
| Indicator | EXG | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 27.45 | 38.25 |
| Support Level | $8.25 | N/A |
| Resistance Level | $9.63 | $22.28 |
| Average True Range (ATR) | 0.19 | 1.34 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 1.89 | 12.50 |
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.